arrow
F

Fabio Marazzi

Fondazione Policlinico Universitario A. Gemelli IRCCS
H指数:16
被引数:770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors)

乳腺癌肉瘤和恶性叶状肿瘤的长期预后:BEAM∗研究组的20年观察性分析。(∗乳腺癌肉瘤欧洲协会)

2025-07-080
OA
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study

新辅助治疗后乳腺癌复发的预测风险因素:NEORISK研究

2025-06-140
PRE
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors

乳腺恶性间叶组织肿瘤:原发性肉瘤和恶性分叶状肿瘤的当前挑战与新展望

2025-04-200
OA
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria

影像组学在预测局部晚期乳腺癌患者早期疾病复发中的作用:影像组学特征与RECIST标准的整合

2025-03-210
PRE
Gender role in radiotherapy: psychosocial differences between males and females during cancer care

性别角色在放射疗法中的作用:癌症护理期间男性和女性之间的心理社会差异

2025-03-060
PRE
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study

根据HER2评分(低 vs. 评分0)的激素受体阳性HER2阴性早期乳腺癌新辅助化疗的活性与疗效:一项回顾性研究

2025-03-050
PRE
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
2025-02-050
OA
Multigenic panels in breast cancer: Clinical utility and management of patients with pathogenic variants other than BRCA1/2
2024-09-010
PRE
Outcomes of Radiotherapy in Oligoprogressive Breast Cancer
2024-07-291
OAAI
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year Experience
2024-06-231
OAAI
An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy

新辅助化疗后乳腺癌最佳手术选择的创新评分系统

2023-08-212
OAAI
Ways to improve breast cancer patients' management and clinical outcome: The 2020 Assisi Think Tank Meeting
2022-09-013
OAAI